Protective Effects of Epigallocatechin Gallate Following 3-nitropropionic Acid-induced Brain Damage: Possible Nitric Oxide Mechanisms

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2009 Sep 19

PMID 19763544

Citations 16

Authors

Puneet Kumar

Anil Kumar

Affiliations

Soon will be listed here.

Abstract

Introduction: The role of oxidative stress has been well known in neurodegenerative disorders. 3-Nitropropionic acid (3-NP) is a plant-based mycotoxin that produces HD like symptoms in animals. Oxidative stress and nitric oxide mechanisms have been recently proposed in the 3-NP-induced neurotoxicity. Epigallocatechin gallate (EGCG) is one of the major components of green tea, known for its potent antioxidant activity. Besides, neuroprotective effect of EGCG has also been suggested in different experimental models.

Objectives: The present study has been designed to examine possible effect of EGCG against 3-NP induced behavioral, oxidative stress, mitochondrial dysfunction, and striatal damage in rats and its possible interaction with nitric oxide modulators.

Material And Methods: Systemic 3-NP (10 mg/kg) administration for 14 days significantly reduced locomotor activity, body weight, grip strength, oxidative defense (raised levels of lipid peroxidation, nitrite concentration, depletion of antioxidant enzyme), and mitochondrial enzymes activity in striatum, cortex, and hippocampal regions of the brain.

Results: Fourteen days of EGCG pretreatment (10, 20, and 40 mg/kg) significantly attenuated behavioral alterations, oxidative damage, mitochondrial complex enzymes dysfunction, and striatal damage in 3-NP-treated animals. L-arginine (50 mg/kg) pretreatment with sub-effective dose of EGCG (20 mg/kg) significantly reversed the protective behavioral, biochemical, cellular, and histological effects of EGCG. However, L-NAME (10 mg/kg) pretreatment with EGCG (20 mg/kg) significantly potentiated the protective effect of EGCG which was significant as compared to their effect per se.

Conclusion: The present study shows that EGCG attenuate 3-NP-induced neurotoxicity, and nitric oxide modulation might be involved in its protective action.

Citing Articles

Epigallocatechin 3-gallate-induced neuroprotection in neurodegenerative diseases: molecular mechanisms and clinical insights.

Islam M, Rauf A, Akter S, Akter H, Al-Imran M, Islam S Mol Cell Biochem. 2025; .

PMID: 39832108 DOI: 10.1007/s11010-025-05211-4.

Catechins and Proanthocyanidins Involvement in Metabolic Syndrome.

Patane G, Putaggio S, Tellone E, Barreca D, Ficarra S, Maffei C Int J Mol Sci. 2023; 24(11).

PMID: 37298181 PMC: 10252413. DOI: 10.3390/ijms24119228.

The Emerging Landscape of Natural Small-molecule Therapeutics for Huntington's Disease.

Bhat S, Ahamad S, Dar N, Siddique Y, Nazir A Curr Neuropharmacol. 2023; 21(4):867-889.

PMID: 36797612 PMC: 10227909. DOI: 10.2174/1570159X21666230216104621.

A Comprehensive Review on Beneficial Effects of Catechins on Secondary Mitochondrial Diseases.

Chen B, Zhang W, Lin C, Zhang L Int J Mol Sci. 2022; 23(19).

PMID: 36232871 PMC: 9569714. DOI: 10.3390/ijms231911569.

Regulation of mitochondrial dysfunction induced cell apoptosis is a potential therapeutic strategy for herbal medicine to treat neurodegenerative diseases.

Li R, Wang L, Duan H, Zhang Q, Guo X, Wu C Front Pharmacol. 2022; 13:937289.

PMID: 36210852 PMC: 9535092. DOI: 10.3389/fphar.2022.937289.

References

Sutherland B, Shaw O, Clarkson A, Jackson D, Sammut I, Appleton I . Neuroprotective effects of (-)-epigallocatechin gallate following hypoxia-ischemia-induced brain damage: novel mechanisms of action. FASEB J. 2004; 19(2):258-60. DOI: 10.1096/fj.04-2806fje. View

Matthews R, Yang L, Jenkins B, Ferrante R, Rosen B, Kaddurah-Daouk R . Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neurosci. 1998; 18(1):156-63. PMC: 6793381. View

Garcia E, Limon D, Perez-De la Cruz V, Giordano M, Diaz-Munoz M, Maldonado P . Lipid peroxidation, mitochondrial dysfunction and neurochemical and behavioural deficits in different neurotoxic models: protective role of S-allylcysteine. Free Radic Res. 2008; 42(10):892-902. DOI: 10.1080/10715760802506356. View

Picconi B, Passino E, Sgobio C, Bonsi P, Barone I, Ghiglieri V . Plastic and behavioral abnormalities in experimental Huntington's disease: a crucial role for cholinergic interneurons. Neurobiol Dis. 2005; 22(1):143-52. DOI: 10.1016/j.nbd.2005.10.009. View

Xie D, Liu G, Zhu G, Wu W, Ge S . (-)-Epigallocatechin-3-gallate protects cultured spiral ganglion cells from H2O2-induced oxidizing damage. Acta Otolaryngol. 2004; 124(4):464-70. DOI: 10.1080/00016480410018278. View

Kumar P, Padi S, NAIDU P, Kumar A . Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fundam Clin Pharmacol. 2007; 21(3):297-306. DOI: 10.1111/j.1472-8206.2007.00485.x. View

Nam E, Lee S, Koh S, Joo W, Maeng S, Im H . Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum. Brain Res. 2005; 1046(1-2):90-6. DOI: 10.1016/j.brainres.2005.03.053. View

Fontaine M, Geddes J, Banks A, Butterfield D . Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. J Neurochem. 2000; 75(4):1709-15. DOI: 10.1046/j.1471-4159.2000.0751709.x. View

Liu Y, Peterson D, Kimura H, Schubert D . Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J Neurochem. 1997; 69(2):581-93. DOI: 10.1046/j.1471-4159.1997.69020581.x. View

10.

WILLS E . Mechanisms of lipid peroxide formation in animal tissues. Biochem J. 1966; 99(3):667-76. PMC: 1265056. DOI: 10.1042/bj0990667. View

11.

Dykens J . Isolated cerebral and cerebellar mitochondria produce free radicals when exposed to elevated CA2+ and Na+: implications for neurodegeneration. J Neurochem. 1994; 63(2):584-91. DOI: 10.1046/j.1471-4159.1994.63020584.x. View

12.

Lin Y, Lin J . (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol Pharmacol. 1997; 52(3):465-72. View

13.

Zeevalk G, Nicklas W . NMDA receptor involvement in toxicity to dopamine neurons in vitro caused by the succinate dehydrogenase inhibitor 3-nitropropionic acid. J Neurochem. 1995; 64(1):455-8. DOI: 10.1046/j.1471-4159.1995.64010455.x. View

14.

Lee S, Kim S, Kim J . Protective effect of topiramate against hippocampal neuronal damage after global ischemia in the gerbils. Neurosci Lett. 2000; 281(2-3):183-6. DOI: 10.1016/s0304-3940(00)00847-8. View

15.

Anderson R, Fisher L, Hara Y, Harris T, Mak W, Melton L . Green tea catechins partially protect DNA from (.)OH radical-induced strand breaks and base damage through fast chemical repair of DNA radicals. Carcinogenesis. 2001; 22(8):1189-93. DOI: 10.1093/carcin/22.8.1189. View

16.

Deshpande S, Hida H, Takei-Io N, Masuda T, Baba H, Nishino H . Involvement of nitric oxide in 3-nitropropionic acid-induced striatal toxicity in rats. Brain Res. 2006; 1108(1):205-15. DOI: 10.1016/j.brainres.2006.06.032. View

17.

Turan N, Csonka C, Csont T, Giricz Z, Fodor G, Bencsik P . The role of peroxynitrite in chemical preconditioning with 3-nitropropionic acid in rat hearts. Cardiovasc Res. 2006; 70(2):384-90. DOI: 10.1016/j.cardiores.2005.12.012. View

18.

Tunez I, Santamaria A . [Model of Huntington's disease induced with 3-nitropropionic acid]. Rev Neurol. 2009; 48(8):430-4. View

19.

Suganuma M, Okabe S, Oniyama M, Tada Y, Ito H, Fujiki H . Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis. 1998; 19(10):1771-6. DOI: 10.1093/carcin/19.10.1771. View

20.

Perez-De la Cruz V, Elinos-Calderon D, Robledo-Arratia Y, Medina-Campos O, Pedraza-Chaverri J, Ali S . Targeting oxidative/nitrergic stress ameliorates motor impairment, and attenuates synaptic mitochondrial dysfunction and lipid peroxidation in two models of Huntington's disease. Behav Brain Res. 2008; 199(2):210-7. DOI: 10.1016/j.bbr.2008.11.037. View